Direct-acting antiviral treatment of hepatitis C virus improved glycemic control for patients with type 2 diabetes.
Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the management of hepatitis C virus in the liver transplantation setting.
The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.
For patients with HCV and HIV coinfection, treatment is effective with standardized nurse/pharmacist support at urban clinics.
The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.
Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of hepatitis C virus.
A combination pill of sofosbuvir, velpatasvir, and voxilaprevir is nearly 100% effective in curing hepatitis C in patients whose disease returned after treatment with direct-acting antiviral agents.
Next-generation metagenomic sequencing can detect a new RNA virus, human hepegivirus-1.
Hepatitis C virus infection may increase the risk for type 2 diabetes, but whether a causal relationship exists is unclear. Screening for type 2 diabetes in this population may have important public health implications.
Hepatitis B virus reactivation has become a safety concern in patients with HBV and HCV coinfection receiving direct-acting antiviral agents.
Researchers evaluated the safety and efficacy of transplantation of kidneys from HCV genotype 1-viremic donors into HCV-negative patients, followed by elbasvir-grazoprevir (Zepatier) treatment.
Hepatitis C virus infections among pregnant women have nearly doubled between 2009 and 2014 in the United States according to the CDC.
Researchers found that there was a doubling in the number of reproductive-aged women with acute and past or present HCV infection in the National Notifiable Disease Surveillance System.
The CDC reports that new hepatitis C virus infections in the US have nearly tripled over 5 years.
Passage of the 2017 budget, along with congressional approval of the AHCA, leaves large holes in the funding of the proposed national approach to infectious disease control.
An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.
Findings from the EXPEDITION-1 study, a phase 3 trial, evaluated the efficacy and safety of glecaprevir/pibrentasvir for the treatment of chronic HCV infection in patients with genotype 1, 2, 4, 5, or 6 and compensated cirrhosis.
Investigational dosage of once-daily ledipasvir/sofosbuvir was safe and highly efficacious in children age 6 to 11 with chronic HCV infection.
Patients with chronic HCV infection who have achieved a sustained virologic response with treatment are considered cured, but they may still be at risk for complications such as hepatocellular carcinoma. The American Gastroenterological Association Institute addresses these issues in its clinical practice update on managing patients cured of HCV infection.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and, to a lesser extent, in patients with alcohol-induced cirrhosis. Mortality rates were also reduced in statin users with HBV-related cirrhosis.
While prior studies have found an association between hepatitis C and the risk for Parkinson disease, the association between hepatitis B and Parkinson disease is new and needs further confirmation.
Despite being the seventh leading cause of death in the world, viral hepatitis accounts for less than 1% of the National Institutes of Health research budget.
Clinical pharmacists can encourage preventive measures on reducing HCV transmission, increase education adherence, assist in initiating HCV treatment, assist in monitoring clinical and adverse effects, and facilitate medication acquisition.
Harvoni (ledipasvir and sofosbuvir) has been approved for children with HCV genotype 1, 4, 5, or 6 infection. Sovaldi (sofosbuvir) has been approved for children with HCV genotype 2 or 3 infection, in combination with ribavirin.
HCV infection is associated with an increased risk for cataract formation, possibly due to HCV-related oxidative stress. Some treatment regimens, such as interferon/ribavirin combination therapy, also increase the risk for cataracts.
Hepatitis B virus reactivation may occur in patients with chronic hepatitis C with current HBV infection treated with direct-acting antivirals.
Several direct-acting antiviral regimens were shown to be safe, tolerable, and efficient in treating hepatitis C virus genotype 1 infection.
The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.
FDA expanded indication for Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie) and added a boxed warning for treatment of patients with HCV infection with compensated cirrhosis.
Of 76.2 million baby boomers in the US in 2015, only 10.5 million had been tested for hepatitis C, according to new research.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Antibiotic-Resistant Bacteria Have Long Resided on Ready-to-Eat Foods
- Infections Complicate Biologic Use in Autoimmune Inflammatory Disorders
- Tuberculosis Vaccine May Reverse Type 1 Diabetes
- No Benefits Seen for Adjunctive Clindamycin in Cellulitis
- Telbivudine During Early Pregnancy Prevents HBV Transmission
- Maternal Antibodies Hinder Antigenic Responses to Vaccines in Infants
- Sepsis-Related Mortality Decreased With Rapid Implementation of Protocol
- New Assay Targets Susceptibility to Ciprofloxacin in Gonorrhea
- Gut Microbiota Associated With Parkinson's Disease Progression
- Decrease Rate of S aureus Resistance Seen With Certain Antibiotics